Clinical Trial Update: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether starting lenvatinib at 18 mg daily offers comparable efficacy to 24 mg with a better safety profile in iodine-131 refractory di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-01-11